Cybin (NYSEAMERICAN:CYBN) Sees Strong Trading Volume

Cybin Inc. (NYSEAMERICAN:CYBN) saw unusually-high trading volume on Monday . Approximately 81,682 shares were traded during mid-day trading, a decline of 39% from the previous session’s volume of 134,133 shares.The stock last traded at $9.37 and had previously closed at $9.18.

Cybin Stock Up 3.7 %

The stock has a market capitalization of $3.91 billion, a P/E ratio of -43.71 and a beta of 0.50.

Cybin (NYSEAMERICAN:CYBN) last issued its earnings results on Thursday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. As a group, analysts expect that Cybin Inc. will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cybin stock. Rathbones Group PLC acquired a new stake in Cybin Inc. (NYSEAMERICAN:CYBN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 65,381 shares of the company’s stock, valued at approximately $26,000. Institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.